CellSource Co., Ltd. (JP:4880) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CellSource Co., Ltd. has announced the establishment of a new subsidiary, Hybrid Medical Co., Ltd., to enhance collaboration with medical institutions in regenerative medicine, especially within orthopedics. The subsidiary will be wholly owned by CellSource and is set to begin operations in November 2024. This strategic move is expected to have a minimal impact on the company’s financial performance for the current fiscal year.
For further insights into JP:4880 stock, check out TipRanks’ Stock Analysis page.